IL1B and acute respiratory distress syndrome: The use of TPE in COVID-19 patients is based on the rationale that by removing the excess of proinflammatory cytokines, such as IL-6, tumor necrosis factor-alpha (TNF-α), and interleukin-1β (IL-1β), TPE can attenuate the cytokine storm and prevent the subsequent multiorgan failure and acute respiratory distress syndrome (ARDS) that are often observed in severe cases.